Clinical Trial Update: Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients [Phase 4]

View source ↗

Summary

Phase 4 trial update indicating Letermovir is being studied for secondary prophylaxis of cytomegalovirus infection in solid organ transplant recipients; status:…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• PREVYMIS (letermovir)

Snippet

Sponsor: Tufts Medical Center | Conditions: Cytomegalovirus Infections, Infection in Solid Organ Transplant Recipients | Phase 4 | Status: RECRUITING